Dr. Voss and Dr. Serzan discuss the evolution of first-line treatment patterns in advanced renal cell carcinoma (RCC) over the past several years, highlighting the transition from tyrosine kinase inhibitor monotherapy toward immune-based combination regimens.
Dr. Martin Voss and Dr. Michael Serzan introduce the evolving treatment landscape for advanced renal cell carcinoma (RCC), emphasizing the importance of individualized first-line treatment selection.
Michael Serzan, MD, discusses the rationale for evaluating botensilimab/balstilimab for patients with advanced renal cell carcinoma.
Michael Serzan, MD, discusses the use of botensilimab/balstilimab in the treatment of patients with advanced renal cell carcinoma.
